Trifunctional NKCE that co-engage two different NK activating receptors, such as CD16 and NKp46, with a tumor target antigen have also been developed, and have shown impressive in vitro activity and suppression of tumor growth in mouse models (110). Here, SLAMF6 is linked to neoplasm.